Figure 1From: Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer Molecular signals believed to be involved in the pathogenesis of DTC. Key events in the initiation of thyroid cancer are believed to include constitutive activation of BRAF, RAS, and RET/PTC [17, 18].Back to article page